文献速递肝胆胰外科围术期管理与 ERAS

胰十二指肠切除术后使用酮咯酸的安全性分析

Comprehensive Analysis of the Effect of Ketorolac Administration after Pancreaticoduodenectomy.
PubMed 文献 · J Am Coll Surg · 2020-02-27

本研究回顾性分析了2008年12月至2018年9月期间429例接受胰十二指肠切除术的患者,根据术后前5天是否使用酮咯酸进行分组。结论认为酮咯酸不增加主要并发症,可用于优化镇痛并减少阿片类药物使用。

要点

  • 酮咯酸组临床相关胰瘘发生率为11.2%,未使用组为6.7%,差异无统计学意义。
  • 两组手术死亡率和主要并发症(Clavien≥3)包括出血和肾衰竭无统计学差异。

核心结论

  • 胰十二指肠切除术后使用酮咯酸与可接受的临床相关胰瘘风险相关,且不增加主要并发症。
  • 数据提示酮咯酸可用于优化镇痛和减少阿片类药物使用的策略中。

研究设计与样本

  • 回顾性研究,纳入2008年12月至2018年9月连续接受胰十二指肠切除术的患者429例。
  • 根据术后前5天是否使用酮咯酸进行分组,主要结局为国际共识定义的临床相关胰瘘。

主要发现

  • 429例患者中,临床相关胰瘘发生率为9.3%(n=40)。
  • 249例(58.0%)患者在术后第6天前使用酮咯酸,平均剂量为36.1 ± 22.3 mg/天。
  • 酮咯酸组临床相关胰瘘发生率为11.2%(n=28),未使用组为6.7%(n=12),p=0.12。
  • 临床相关胰瘘发生率与酮咯酸剂量无关。

临床怎么用

  • 在胰十二指肠切除术后,可考虑使用酮咯酸作为减少阿片类药物使用的镇痛策略之一。
  • 使用酮咯酸时需注意监测临床相关胰瘘等并发症,但现有数据未显示风险显著增加。

局限性

  • 本研究为回顾性综述,可能存在选择偏倚和混杂因素。
  • 酮咯酸使用并非随机分配,组间基线特征可能影响结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Outcome improvement is a major goal of pancreatic surgery. Such efforts include decreasing perioperative narcotic use to optimize care and reduce potential contributions to the opioid crisis. Ketorolac, a frequent component of opioid-minimizing recovery pathways, has not been universally adopted over concerns regarding adverse events including anastomotic fidelity, hemorrhage, and renal failure. We examined ketorolac's effects on pancreatic fistula (PF) formation and related morbidity after pancreaticoduodenectomy (PD). STUDY DESIGN: A retrospective review of consecutive patients undergoing PD from December 2008 to September 2018 was conducted and stratified by receipt of ketorolac during the initial 5 postoperative days. The primary outcome was clinically relevant PF (CR-PF) per international consensus definitions. Secondary outcomes included fistula risk score (FRS)-adjusted CR-PF and cumulative morbidity. RESULTS: Of 429 patients, CR-PF occurred in 9.3% (n = 40), and 249 patients received ketorolac before postoperative day 6 (58.0%), with a mean dose of 36.1 ± 22.3 mg/day. CR-PF occurred in 11.2% (n = 28) of patients receiving ketorolac vs 6.7% (n = 12) who did not ( p = 0.12); CR-PF incidence was unrelated to dose. Overall CR-PF incidence did not differ statistically by ketorolac use in the first 5 days postoperatively across FRS categories. Results from multivariable logistic regression models, adjusted for known PF risk factors suggested that ketorolac was not significantly associated with risk of CR-PF (odds ratio [OR] 1.99 [range 0.93 to 4.26], p = 0.08). Operative mortality and major (Clavien ≥ 3) morbidity, including hemorrhage and renal failure, did not differ statistically between groups. CONCLUSIONS: Ketorolac administration was associated with an acceptable risk of CR-PF and no increase in major morbidity after PD. These data suggest ketorolac can be used in strategies to optimize analgesia and minimize opioid usage.

来源:J Am Coll Surg,查看原文。版权归原作者所有。

引用

  1. Kunstman JW, Brandt WS, Azar SA, et al. Comprehensive Analysis of the Effect of Ketorolac Administration after Pancreaticoduodenectomy. J Am Coll Surg. 2020. PMID: 32113030. doi:10.1016/j.jamcollsurg.2020.02.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。